COMP <GO>
EXEL vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Exelixis Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: EXEL 10
— MRK 5
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: MRK
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
options-implied-move
6.80%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 20.70% | +14.40 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 15.3x | +3.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.34% | 3.42% | +1.92 | EXEL | /fcf-yield <GO> |
| Operating Margin | 37.60% | 34.30% | +3.30 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 33.70% | 28.10% | +5.60 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 1.30% | +5.70 | EXEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 5.19 | +11.45 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.7 | 56.9 | +24.79 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.92 | +0.04 | EXEL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 18.4x | +1.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $361.02B | -$344.62B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | MRK REV | EXEL GROSS % | MRK GROSS % | EXEL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $65.01B | 96.4% | 74.8% | $875.8M | $12.36B |
| FY 2024 | $2.17B | $64.17B | 96.5% | 76.3% | $671.5M | $18.10B |
| FY 2023 | $1.83B | $60.12B | 44.0% | 44.0% | $251.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
MRK // BETA 0.92